{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:15:38Z","timestamp":1788178538777,"version":"build-2803163510"},"reference-count":38,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPD"],"published-print":{"date-parts":[[2022,2,15]]},"abstract":"<jats:p>Background: Biochemical and clinical biomarkers correlate with progression rate and disease severity in Parkinson\u2019s disease (PD) but are not sufficiently studied in late PD. Objective: To examine how serum neurofilament light chain (S-NfL) alone or combined with clinical classifications predicts PD outcome in later disease stages. Methods: Eighty-five patients with 7.9\u00b15.1 years of PD duration were included in an observational cohort. Clinical scores were obtained at two separate examinations 8.2\u00b12.0 years apart. S-NfL levels were determined with single molecule array (SiMoA). Five predefined disease progression milestones were assessed. After affirming combination potential of S-NfL and either of two clinical classifications, three combined models were constructed based on these factors and age at onset in different combinations. Results: S-NfL levels showed significant hazard ratios for four out of five disease progression milestones: walking-aid usage (HR 3.5; 95% CI 1.4\u20138.5), nursing home living (5.1; 2.1\u201312.5), motor end-stage (6.2; 2.1\u201317.8), and death (4.1; 1.7\u20139.7). Higher S-NfL levels were associated with lower ability in activities of daily living and poorer cognition at baseline and\/or at follow-up. Combined models showed significantly improved area under receiver operating characteristic curves (0.77\u20130.91) compared to S-NfL levels alone (0.68\u20130.71) for predicting the five disease milestones. Conclusion: S-NfL levels stratified patients according to their likelihood to reach clinically relevant progression milestones during this long-term observational study. S-NfL alone reflected motor and social outcomes in later stages of PD. Combining S-NfL with clinical factors was possible and exploratory combined models improved prognostic accuracy.<\/jats:p>","DOI":"10.3233\/jpd-212866","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T11:24:10Z","timestamp":1637321050000},"page":"571-584","source":"Crossref","is-referenced-by-count":30,"title":["Serum Neurofilament Light Chain as a Marker of Progression in Parkinson\u2019s Disease: Long-Term Observation and Implications of Clinical Subtypes"],"prefix":"10.1177","volume":"12","author":[{"given":"Emil","family":"Ygland R\u00f6dstr\u00f6m","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences Lund, Neurology, Lund University, Lund, Sweden"},{"name":"Department of Neurology, Sk\u00e5ne University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sk\u00e5ne University Hospital, Lund, Sweden"},{"name":"Department of Clinical Sciences Malm\u00f6, Clinical Memory Research Unit, Lund University, Malm\u00f6, Sweden"},{"name":"Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[{"name":"Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Malm\u00f6, Clinical Memory Research Unit, Lund University, Malm\u00f6, Sweden"},{"name":"Memory Clinic, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Puschmann","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Neurology, Lund University, Lund, Sweden"},{"name":"Department of Neurology, Sk\u00e5ne University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JPD-212866_ref1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/ejn.14094","article-title":"The clinical heterogeneity of Parkinson\u2019s disease and its therapeutic implications","volume":"49","author":"Greenland","year":"2019","journal-title":"Eur J Neurosci"},{"key":"10.3233\/JPD-212866_ref2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.parkreldis.2015.04.029","article-title":"Clinically meaningful parameters of progression and long-term outcome of Parkinson disease: An international consensus statement","volume":"21","author":"Puschmann","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-212866_ref3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamaneurol.2013.6233","article-title":"Parkinson disease subtypes","volume":"71","author":"Thenganatt","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.3233\/JPD-212866_ref4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","article-title":"CSF and blood biomarkers for Parkinson\u2019s disease","volume":"18","author":"Parnetti","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-212866_ref5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/jnnp-2018-318337","article-title":"Developing and validating Parkinson\u2019s disease subtypes and their motor and cognitive progression","volume":"89","author":"Lawton","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-212866_ref6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/mds.25652","article-title":"Relation of clinical subtypes in Parkinson\u2019s disease with survival","volume":"29","author":"de Lau","year":"2014","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212866_ref7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fnagi.2017.00301","article-title":"Parkinson\u2019s disease subtypes identified from cluster analysis of motor and non-motor symptoms","volume":"9","author":"Mu","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JPD-212866_ref8","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/brain\/awx118","article-title":"Clinical criteria for subtyping Parkinson\u2019s disease: biomarkers and longitudinal progression","volume":"140","author":"Fereshtehnejad","year":"2017","journal-title":"Brain"},{"key":"10.3233\/JPD-212866_ref9","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.parkreldis.2015.09.048","article-title":"Biomarkers in Parkinson\u2019s disease: Advances and strategies","volume":"22 Suppl 1","author":"Delenclos","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-212866_ref10","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-212866_ref11","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.3233\/JPD-212866_ref12","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder","volume":"88","author":"Hansson","year":"2017","journal-title":"Neurology"},{"key":"10.3233\/JPD-212866_ref13","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","article-title":"Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders","volume":"69","author":"Hall","year":"2012","journal-title":"Arch Neurol"},{"key":"10.3233\/JPD-212866_ref14","doi-asserted-by":"crossref","first-page":"e1479","DOI":"10.1212\/WNL.0000000000007179","article-title":"Serum NFL discriminates Parkinson disease from atypical parkinsonisms","volume":"92","author":"Marques","year":"2019","journal-title":"Neurology"},{"key":"10.3233\/JPD-212866_ref15","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1212\/WNL.0000000000010084","article-title":"NfL as a biomarker for neurodegeneration and survival in Parkinson disease","volume":"95","author":"B\u00e4ckstr\u00f6m","year":"2020","journal-title":"Neurology"},{"key":"10.3233\/JPD-212866_ref16","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/mds.28206","article-title":"Validation of serum neurofilament light chain as a biomarker of Parkinson\u2019s disease progression","volume":"35","author":"Mollenhauer","year":"2020","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212866_ref17","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/mds.28056","article-title":"CSF NFL in a longitudinally assessed PD cohort: age effects and cognitive trajectories","volume":"35","author":"Lerche","year":"2020","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212866_ref18","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/mds.28026","article-title":"Intraindividual neurofilament dynamics in serum mark the conversion to sporadic Parkinson\u2019s disease","volume":"35","author":"Wilke","year":"2020","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212866_ref19","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1212\/WNL.40.10.1529","article-title":"Variable expression of Parkinson\u2019s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group","volume":"40","author":"Jankovic","year":"1990","journal-title":"Neurology"},{"key":"10.3233\/JPD-212866_ref20","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.14336\/AD.2019.0112","article-title":"Subtyping of Parkinson\u2019s disease - where are we up to?","volume":"10","author":"Qian","year":"2019","journal-title":"Aging Dis"},{"key":"10.3233\/JPD-212866_ref21","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/mds.20897","article-title":"Changes in motor subtype and risk for incident dementia in Parkinson\u2019s disease","volume":"21","author":"Alves","year":"2006","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212866_ref22","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/mds.26657","article-title":"Motor subtype in Parkinson\u2019s disease: Different disorders or different stages of disease?","volume":"31","author":"Nutt","year":"2016","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212866_ref23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.parkreldis.2016.04.027","article-title":"How stable are Parkinson\u2019s disease subtypes in de novo patients: Analysis of the PPMI cohort?","volume":"28","author":"Simuni","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-212866_ref24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41531-021-00208-4","article-title":"Clinical classification systems and long-term outcome in mid- and late-stage Parkinson\u2019s disease","volume":"7","author":"Ygland R\u00f6dstr\u00f6m","year":"2021","journal-title":"NPJ Parkinsons Dis"},{"key":"10.3233\/JPD-212866_ref25","doi-asserted-by":"crossref","first-page":"101986","DOI":"10.1016\/j.nicl.2019.101986","article-title":"Assessment of a prognostic MRI biomarker in early de novo Parkinson\u2019s disease","volume":"24","author":"Zeighami","year":"2019","journal-title":"Neuroimage Clin"},{"key":"10.3233\/JPD-212866_ref26","doi-asserted-by":"crossref","first-page":"102111","DOI":"10.1016\/j.nicl.2019.102111","article-title":"Predicting severity and prognosis in Parkinson\u2019s disease from brain microstructure and connectivity","volume":"25","author":"Abbasi","year":"2020","journal-title":"Neuroimage Clin"},{"key":"10.3233\/JPD-212866_ref27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.parkreldis.2015.02.010","article-title":"Biomarkers of cognitive decline in Parkinson\u2019s disease","volume":"21","author":"Lin","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-212866_ref28","volume-title":"Recent developments in Parkinson\u2019s disease, volume II","author":"Fahn","year":"1987"},{"key":"10.3233\/JPD-212866_ref29","unstructured":"Schwab R , England A , Schwab Z (1969) Projection technique for evaluating surgery in Parkinson\u2019s disease."},{"key":"10.3233\/JPD-212866_ref30","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1212\/WNL.0000000000002768","article-title":"Postural instability and gait are associated with severity and prognosis of Parkinson disease","volume":"86","author":"van der Heeden","year":"2016","journal-title":"Neurology"},{"key":"10.3233\/JPD-212866_ref31","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"10.3233\/JPD-212866_ref32","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/mds.26578","article-title":"Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson\u2019s disease","volume":"31","author":"Hall","year":"2016","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212866_ref33","doi-asserted-by":"crossref","first-page":"17368","DOI":"10.1038\/s41598-018-35766-w","article-title":"Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease","volume":"8","author":"Lin","year":"2018","journal-title":"Sci Rep"},{"key":"10.3233\/JPD-212866_ref34","doi-asserted-by":"crossref","first-page":"e1104","DOI":"10.1212\/WNL.0000000000008088","article-title":"Blood NfL: A biomarker for disease severity and progression in Parkinson disease","volume":"93","author":"Lin","year":"2019","journal-title":"Neurology"},{"key":"10.3233\/JPD-212866_ref35","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaneurol.2018.3746","article-title":"Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders","volume":"76","author":"Olsson","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.3233\/JPD-212866_ref36","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/jnnp-2013-305277","article-title":"The CamPaIGN study of Parkinson\u2019s disease: 10-year outlook in an incident population-based cohort","volume":"84","author":"Williams-Gray","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-212866_ref37","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/jnnp-2014-308786","article-title":"Parkinson\u2019s disease beyond 20 years","volume":"86","author":"Cilia","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-212866_ref38","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/JPD-202472","article-title":"Parkinson\u2019s disease subtypes: critical appraisal and recommendations","volume":"11","author":"Mestre","year":"2021","journal-title":"J Parkinsons Dis"}],"container-title":["Journal of Parkinson's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JPD-212866","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:50:55Z","timestamp":1777611055000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JPD-212866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":38,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jpd-212866","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]}}}